<DOC>
	<DOC>NCT00475878</DOC>
	<brief_summary>This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.</brief_summary>
	<brief_title>SSRI and Buprenorphine</brief_title>
	<detailed_description>Participants interested in receiving Buprenorphine will be offered the opportunity to enroll in this study. Enrolled study participants will complete interviews at baseline and again every two weeks for a total of 8 interviews over 3 months. In this double-blind randomized controlled trial, participants will either receive a placebo or escitalopram (10mg). All participants will also be followed by their Buprenorphine clinic medical provider. Questions during the face-to-face interviews will assess mood, drug craving, pain, sleep, medication adherence and drug-related experiences. Comparison(s): Participants randomized into the medication component of the study as compared to participants randomized into the placebo component of the study.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>opiate dependence HamD &gt; 14 no psychiatric contraindications to using escitalopram no medical contraindications to using escitalopram methadone dose &lt; 30 no current SSRI use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>opiate use</keyword>
	<keyword>depression</keyword>
	<keyword>buprenorphine</keyword>
	<keyword>escitalopram</keyword>
</DOC>